Robert Wild

2.5k total citations
41 papers, 1.7k citations indexed

About

Robert Wild is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Robert Wild has authored 41 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 18 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Robert Wild's work include Cancer, Hypoxia, and Metabolism (16 papers), Angiogenesis and VEGF in Cancer (7 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Robert Wild is often cited by papers focused on Cancer, Hypoxia, and Metabolism (16 papers), Angiogenesis and VEGF in Cancer (7 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Robert Wild collaborates with scholars based in United States, Germany and Indonesia. Robert Wild's co-authors include Sundaram Ramakrishnan, X. Yu, Edward H. Egelman, Manju Hingorani, Smita S. Patel, A. Douglas Kinghorn, Subramanian Ramakrishnan, Arjan W. Griffioen, Steven M. Swanson and Prafulla C. Gokhale and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Robert Wild

35 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Wild United States 17 1.3k 325 263 149 145 41 1.7k
Nancy Francoeur United States 15 866 0.7× 234 0.7× 287 1.1× 84 0.6× 148 1.0× 24 1.4k
Yanling Zhang China 25 1.2k 1.0× 289 0.9× 262 1.0× 61 0.4× 119 0.8× 98 1.7k
Yao Kong China 22 1.2k 1.0× 647 2.0× 218 0.8× 172 1.2× 151 1.0× 64 1.9k
Victoria J. Findlay United States 26 1.6k 1.3× 437 1.3× 362 1.4× 37 0.2× 121 0.8× 50 2.2k
K. M. Nicholson United Kingdom 4 1.1k 0.9× 227 0.7× 380 1.4× 55 0.4× 82 0.6× 6 1.5k
Anne‐Marie Faussat France 26 1.1k 0.9× 242 0.7× 648 2.5× 57 0.4× 111 0.8× 46 1.9k
Yong-Nyun Kim South Korea 14 909 0.7× 446 1.4× 353 1.3× 69 0.5× 111 0.8× 31 1.5k
Lih‐Ching Hsu Taiwan 21 1.0k 0.8× 231 0.7× 371 1.4× 40 0.3× 263 1.8× 62 1.4k
Hong Gao China 22 1.1k 0.9× 580 1.8× 245 0.9× 73 0.5× 75 0.5× 49 1.8k
Lihong Chen China 20 1.1k 0.9× 297 0.9× 478 1.8× 95 0.6× 80 0.6× 50 1.7k

Countries citing papers authored by Robert Wild

Since Specialization
Citations

This map shows the geographic impact of Robert Wild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Wild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Wild more than expected).

Fields of papers citing papers by Robert Wild

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Wild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Wild. The network helps show where Robert Wild may publish in the future.

Co-authorship network of co-authors of Robert Wild

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Wild. A scholar is included among the top collaborators of Robert Wild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Wild. Robert Wild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jin, Chen, David Moon, Hong Zhang, et al.. (2025). Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress. Clinical Cancer Research. 31(20). 4345–4360.
2.
3.
Scheel, Andreas H., Margaret Dugan, Robert Wild, et al.. (2024). Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score. npj Precision Oncology. 8(1). 259–259.
4.
Allevato, Michael M., Keiichi Koshizuka, Daniela Nachmanson, et al.. (2024). A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death. Cancer Letters. 598. 217089–217089. 8 indexed citations
5.
Moon, David, Lingfan Xu, Fan Zhang, et al.. (2023). Targeting glutamine dependence with DRP‐104 inhibits proliferation and tumor growth of castration‐resistant prostate cancer. The Prostate. 84(4). 349–357. 6 indexed citations
6.
Encarnación-Rosado, Joel, Albert S.W. Sohn, Douglas E. Biancur, et al.. (2023). Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nature Cancer. 5(1). 85–99. 65 indexed citations
7.
8.
Bhagwat, Shripad V., Prafulla C. Gokhale, Andrew P. Crew, et al.. (2011). Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin. Molecular Cancer Therapeutics. 10(8). 1394–1406. 159 indexed citations
9.
McKinley, Eliot T., Joseph E. Bugaj, Ping Zhao, et al.. (2011). 18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer. Clinical Cancer Research. 17(10). 3332–3340. 41 indexed citations
10.
Buck, Elizabeth, Prafulla C. Gokhale, Susan Koujak, et al.. (2010). Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer. Molecular Cancer Therapeutics. 9(10). 2652–2664. 183 indexed citations
11.
Wild, Robert, et al.. (2010). Lipids from Lipomyces starkeyi. SHILAP Revista de lepidopterología. 53 indexed citations
12.
Valentine, Peter, et al.. (2008). Sitios Naturales Sagrados: directrices para administradores de áreas protegidas. IUCN eBooks.
13.
Kim, So-Young, Bang Yeon Hwang, Bao‐Ning Su, et al.. (2007). Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7.. PubMed. 27(4B). 2175–83. 82 indexed citations
14.
Rosenfeld-Franklin, Maryland, Caroline Pirritt, Darla Landfair, et al.. (2007). In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). Molecular Cancer Therapeutics. 6. 5 indexed citations
15.
Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations
16.
Wild, Robert, Ruud P.M. Dings, Indira V. Subramanian, & Sundaram Ramakrishnan. (2004). Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. International Journal of Cancer. 110(3). 343–351. 47 indexed citations
17.
Ramakrishnan, Sundaram, Robert Wild, & Dana Nojima. (2003). Targeting Tumor Vasculature Using VEGF-Toxin Conjugates. Humana Press eBooks. 166. 219–234. 7 indexed citations
18.
19.
Gupta, Kalpna, Pankaj Gupta, Robert Wild, Sundaram Ramakrishnan, & Robert P. Hebbel. (1999). Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis. 3(2). 147–158. 118 indexed citations
20.
Wild, Robert, et al.. (1982). [Nutrient and fiber content of infant food].. PubMed. 37(3). 205–13. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy Francoeur Breakdown of academic impact, for papers by Yanling Zhang Breakdown of academic impact, for papers by Yao Kong Breakdown of academic impact, for papers by Victoria J. Findlay Breakdown of academic impact, for papers by K. M. Nicholson Breakdown of academic impact, for papers by Anne‐Marie Faussat Breakdown of academic impact, for papers by Yong-Nyun Kim Breakdown of academic impact, for papers by Lih‐Ching Hsu Breakdown of academic impact, for papers by Hong Gao Breakdown of academic impact, for papers by Lihong Chen
Rankless by CCL
2026